

# End of Study Regulatory Compliance

Erin Bengelink  
Site Manager  
SIREN CCC  
University of Michigan



**Established  
Status  
Epilepticus  
Treatment  
Trial**

# Ongoing Responsibilities for Active Sites

- It is the responsibility of each Hub/Site to maintain regulatory compliance
- Site documents and people documents must be kept current in the ESETT Database
- Study team personnel whose regulatory compliance lapses cannot participate in trial related activities



# During PD Activities

- Spokes

*Applies to: All Spokes who enrolled 1 or more ESETT subjects.*

- FWA
- Current IRB Approval (version 2 of protocol)
- FDA Form 1572
- Electronic Delegation of Authority (eDOA) Log

- People

*Applies to: At minimum, the Hub PI, Trial PI and Primary Study Coordinator; any other team members participating in PD Activities.*

- CV
- Medical License
- HSP Certification
- GCP Certification



# Post-PD Activities

- Inform IRB of final study close out following conclusion of PD events.
- Upload documentation from the IRB regarding final study closure once PD events have concluded in WebDCU under: IRB Close-out Acknowledgement.
- Update the eDOA log to reflect end of study: Add end dates for all active team members to correspond with IRB closure of the trial.
- Maintain regulatory compliance in WebDCU until above items are completed.



# Questions?

- [Esett-milestone@umich.edu](mailto:Esett-milestone@umich.edu)





**Established  
Status  
Epilepticus  
Treatment  
Trial**

[esett.org](http://esett.org)